Editorial on Evolving Landscape of the Management of Glioblastoma1
Introduction to the evolving landscape of the management of glioblastoma
Chinese Clinical Oncology
2021;
10
(4)
:34
.
(25 August 2021)
Review Article on Evolving Landscape of the Management of Glioblastoma1
A view of the epidemiologic landscape: how population-based studies can lend novel insights regarding the pathophysiology of glioblastoma
Chinese Clinical Oncology
2021;
10
(4)
:35
.
(25 August 2021)
Tumor treating fields in neuro-oncology: integration of alternating electric fields therapy into promising treatment strategies
Chinese Clinical Oncology
2021;
10
(4)
:36
.
(25 August 2021)
Anti-angiogenic therapies in the management of glioblastoma
Chinese Clinical Oncology
2021;
10
(4)
:37
.
(25 August 2021)
The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results
Chinese Clinical Oncology
2021;
10
(4)
:38
.
(25 August 2021)
Radiotherapy intensification for glioblastoma: enhancing the backbone of treatment
Chinese Clinical Oncology
2021;
10
(4)
:39
.
(25 August 2021)
Editorial on Evolving Landscape of the Management of Glioblastoma1
An international perspective on the management of glioblastoma
Chinese Clinical Oncology
2021;
10
(4)
:40
.
(25 August 2021)
Editorial Commentary on Evolving Landscape of the Management of Glioblastoma1
Management of glioblastoma: a perspective from Lithuania
Chinese Clinical Oncology
2021;
10
(4)
:41
.
(25 August 2021)
Management of glioblastoma: an Australian perspective
Chinese Clinical Oncology
2021;
10
(4)
:42
.
(25 August 2021)
Management of glioblastoma: a perspective from Nigeria
Chinese Clinical Oncology
2021;
10
(4)
:43
.
(25 August 2021)
Review Article on Evolving Landscape of the Management of Glioblastoma1
Management of glioblastoma: a perspective from Mexico
Chinese Clinical Oncology
2021;
10
(4)
:44
.
(25 August 2021)
Disclosure:
1. The series “The Evolving Landscape of The Management of Glioblastoma” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Rimas V. Lukas served as the unpaid Guest Editor for the series.
